Biopharmaceutical company Promomed has established LLC Promomed‑Pharma to operate in the Uzbek market. Creation of a local company will make it possible to establish direct contacts with the medical and pharmaceutical communities and business partners, build predictable supply channels for socially significant medications, and ensure a stable market presence...

Promomend company has completed the development cycle for one of the most advanced HIV treatment regimens, which was previously unavailable in Russia. Сombination of medications includes tablet and injectable forms of cabotegravir and rilpivirine. All four medications have already received registration certificates, and the combination of cabotegravir and ri...

According to preliminary data, Promomed’s revenue for the first six months of 2026 increased by 76%. The company will publish its operational results and IFRS financial statements on August 31, 2026.

Promomed's net profit under RAS for 6 months of 2026 amounted to ₽2.94 billion, an increase of 47.4 times compared to ₽0.062 billion in the previous year.